Regeneron Pharmaceuticals Stock Price, News & Analysis

Viz.ai has announced a multi-year partnership with Sanofi (SNY) and Regeneron (REGN) to develop and evaluate an AI-powered workflow solution for Chronic Obstructive Pulmonary Disease (COPD). The collaboration will focus on deploying the Viz COPD module, which uses electronic health record (EHR) data and artificial intelligence to improve detection and management of high-risk COPD patients.

The solution will be implemented across Viz.ai's network of over 1,700 hospitals and health systems, reaching more than 60,000 healthcare providers. COPD, affecting an estimated 392 million people globally and ranking as the fourth leading cause of death worldwide, remains underprioritized and undertreated. The AI-powered system will screen and triage patients using natural language processing, aligning with established clinical guidelines to identify high-risk individuals requiring follow-up care.

At the 75th Regeneron International Science and Engineering Fair (ISEF), nearly 1,700 young scientists from 48 U.S. states and 60+ countries competed for over $9 million in awards. The top prize, the $100,000 George D. Yancopoulos Innovator Award, went to Adam Kovalčík from Slovakia for developing a more efficient and cost-effective method to produce the antiviral drug galidesivir, reducing production costs from $75/gram to $12.50/gram.

Other major winners included Benjamin Davis ($75,000) for a desktop plastic recycling system, Siyaa Poddar ($75,000) for toxic dust detection technology, and a team of three students ($50,000) for developing a brain-controlled bionic prosthetic leg. The competition, sponsored by Regeneron Pharmaceuticals (NASDAQ: REGN), celebrated its milestone 75th year of fostering STEM innovation and has provided STEM experiences to over 3.2 million students since 2020.